Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NRG-LU005 chemoradiation with or without atezolizumab in limited-stage small cell lung cancer
jRCT2031210107Phase 3Active, not recruiting
- Sponsor
- NRG Oncology
- Start
- Jun 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
01
Overview
Phase 3, randomised, open-label trial of atezolizumab in small cell lung cancer (SCLC) (2 arms), sponsored by NRG Oncology. Primary endpoint: overall survival. Started Jun 2021; status: active, not recruiting.
02
Drugs
atezolizumab
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on jRCT2031210107.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031210107.